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Abstract
Background: Endometriosis, which shares certain characteristics with cancers, may cause abnormal expression of
proteins involved in cell migration. Endometrial epithelial cells (EECs) are believed to play an important role in
endometriotic migration. The aim of this study was to investigate the relationship between the expression of
osteopontin (OPN) and matrix metalloproteinase-9 (MMP-9) in endometriotic migration.
Methods: We performed primary culture of EECs and investigated the expression of OPN and MMP-9 in EECs
regulated by 17beta-estradiol (E2). OPN-specific siRNA interference was used to down-regulate OPN and to explore
the corresponding change in MMP-9 expression. Real-time RT-PCR, western blot analysis and flow cytometry were
used to determine the expression levels of OPN and MMP-9. Gelatin zymography was performed to observe the
enzymatic activity of MMP-9 in conditioned media. Transwell and wound scratch assays were performed to
investigate the migration ability of EECs.
Results: The expression levels of OPN and MMP-9 in normal EECs (NEECs) were inferior to those in EECs from patients
with endometriosis (EEECs). The expression levels of OPN and MMP-9 from stage III/IV EEECs and secretory-phase EECs
were higher than those of stage I/II EEECs or proliferative-phase EECs. The expression levels of OPN and MMP-9 in
EEECs were increased by E2 treatment and remarkably decreased by siRNA interference. Active MMP-9 expression
increased with E2 treatment and decreased with siRNA treatment in EEECs compared with the same treatments in
NEECs. The migratory abilities of EEECs were enhanced after cells were treated with E2; in contrast, these abilities were
reduced by siRNA interference. In NEECs, active MMP-9 and cellular migration abilities were only minimally influenced
by E2 and siRNA treatment.
Conclusions: The present study suggests that the up-regulation of MMP-9 via activation of OPN induced by estrogen
may correlate with the migration of endometrial epithelial cells in patients with endometriosis.
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Introduction
Endometriosis is a common chronic gynecological disease
affecting 10 % of women of child-bearing age. Symptoms
include dysmenorrhea, chronic pelvic pain, menorrhagia
and infertility. Individual susceptibility to endometriosis
includes a complex interaction of genetic, hormonal and
environmental factors [1]. Although several theories, such
as retrograde menstruation, coelomic metaplasia and Mül-
lerianosis, have been proposed to explain its etiology, the
molecular mechanisms of this disease remain unclear.
Endometriosis can cause endometrial cells to invade
and metastasize to various organs and even compromise
the functions of these organs. In a sense, endometriosis
shares some similar characteristics with cancers [2]. Many
proteins have been found to play roles in the invasion and
metastasis of cancer cells; however, whether these proteins
exert a similar influence on endometrial cells in endomet-
riosis has not yet been fully investigated.
Osteopontin (OPN) is an integrin-binding glycoprotein
that was first discovered in the bone matrix and then
implicated in adhesion, anti-apoptosis and metastasis in
cancer cells [3, 4]. Matrix metalloproteinase-9 (MMP-9),
also known as the largest gelatinase in the family of
matrix metalloproteinases, is a zinc-dependent endopep-
tidase that facilitates the degradation of type IV collagen
in many cancers. Recently, it was reported that OPN ac-
tivates the PI3-K/Akt pathway, up-regulates HIF-1alpha
via binding to v3 integrins and promotes the degradation
of the extracellular matrix through uPA and MMP-9 to
mediate cancer cell metastasis [5]. Another study has re-
ported that OPN promotes the progression of gastric
cancer by activating matrix metalloproteinase 2 (MMP-2)
and MMP-9 through the NF-kappaB pathway [6]. The
OPN/MMP-9 pathway represents a new molecular mech-
anism involved in cancer metastasis.
OPN and MMP-9 expression levels have been deter-
mined in normal endometrial epithelial cells (NEECs). A
much stronger OPN expression is found in the middle and
late secretory phases compared with the proliferative and
early secretory phases [7, 8]. MMP-9 is much more strongly
expressed in the late secretory phase than in the other
phases of the menstrual cycle [9, 10]. The elevated expres-
sion levels of OPN and MMP-9 in the coincident phase of
the menstrual cycle suggest that there may be a correlation
between the expressions of these two proteins. Various
studies on OPN expression in patients with endometriosis
have provided similar results. OPN mRNA and protein ex-
pression levels, as well as levels of the secreted glycoprotein
in the blood, are remarkably increased in endometriotic le-
sions compared with normal tissues [11, 12]. MMP-9 plays
an important role in the changes in the growing cycle and
tissue breakdown that occur in the endometrium and af-
fects the migration of endometrial cells in endometriotic le-
sions. Several recent studies have examined the increased
expression of MMP-9 in patients with endometriosis [13,
14]. Thus, we hypothesize that a signal-transduction path-
way involving OPN and MMP-9, similar to that in cancer
cells, may play a role in the migration of endometrial epi-
thelial cells (EECs) in endometriotic lesions.
Currently, endometriosis is regarded as an estrogen-
dependent disorder, and the initiation and development
of this disorder can be promoted by systemic or locally
synthesized estrogen [15]. The local concentration of
estrogen is much more extensively regulated by intra-
tissue estrogen metabolism than in the serum [16].
Gonadotropin-releasing hormone agonists (GnRH-a)
and aromatase inhibitors are widely used to treat endo-
metriosis [17, 18]. These agents inhibit the proliferation
and metastasis of endometrial cells and accelerate the
apoptosis of these cells by inducing a low local estrogen
level [19, 20]. Therefore, estrogen at the local level may
be associated with the metastasis and proliferation of
endometrial cells in endometriosis. Currently, the patho-
logical mechanisms by which OPN and MMP-9 levels are
affected by estrogen are not fully elucidated and require
further study. Based on the findings above, we hypothesize
that OPN might up-regulate MMP-9 expression as a re-
sult of the locally increased concentration of estrogen,
which promotes the migration of endometrial cells and
eventually leads to endometriosis.
The present study was designed to explore the regula-
tory correlation between OPN and MMP-9 in EECs. We
performed primary cell culture to acquire highly pure
EECs. Estrogen (17beta-estradiol, E2) was used to influ-
ence OPN and MMP-9 expression in EECs. We exam-
ined expression of MMP-9 and the migratory ability of
EECs after treatment with an OPN-specific siRNA and
E2. Real-time RT-PCR, western blots and flow cytometry
were used to detect the expression levels of OPN and
MMP-9. Gelatin zymography was performed to observe
the enzymatic activity of MMP-9 in conditioned media.
Transwell and wound scratch assays were conducted to
determine the migratory ability of EECs.
Methods
Ethical approval
This study was carried out in accordance with the Declar-
ation of Helsinki. Ethical approval was given by the
Ningxia Medical University Institutional Review Board
(reference number 20130106) on October 4th, 2013. Writ-
ten informed consent was obtained from all of the re-
cruited patients. This study was initiated on November
13th, 2013 and terminated on August 20th, 2014.
Patient recruitment and characterization
AII of the patients recruited in this study were women
of child-bearing age. Thirty-two women with endometri-
osis who had not received hormones or GnRH-a agonist
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treatment for at least six months were recruited before
surgery, and all underwent laparoscopic surgery at the
Department of Obstetrics and Gynecology of General
Hospital, Ningxia Medical University, Ningxia, China.
Among these 32 patients, preoperative diagnosis included
18 with an ovarian cyst and 14 with infertility. Each case
of endometriosis was staged during the operation accord-
ing to the revised American Fertility Society classification
of endometriosis (rAFS) and subsequently confirmed by
histology. Thirty women undergoing tubal ligation for
sterilization were recruited as controls. No minimal endo-
metriosis was found in these control subjects. The endo-
metrium from patients with endometriosis was obtained
by Pipelle biopsy during diagnostic laparoscopy or by uter-
ine curettage for the control subjects. Detailed informa-
tion on the study participants is listed in Table 1.
Primary culture of endometrial epithelial cells
All tissues were washed three times with sterile Hank’s
Balanced Salt Solution (HBSS, phenol red free), minced
into pieces of approximately 1 mm3 and digested in 10 ml
of HBSS containing type IV collagenase (0.03 %; Sigma, St.
Louis, MO) and 10 U/ml DNase I (Sigma) at 37 °C for
40 min. Type IV collagenase is an enzyme that is believed
to degrade cellular mesenchyme such as laminin, type IV
collagen and basal membrane while preserving the integ-
rity of epithelial cells. Next, the undigested tissues were
collected by centrifugation at 500 × g for 1 min, and the
sediment was subjected to another round of digestion for
40 min. Epithelial cells and stromal cells in the super-
natant were separated by differential centrifugation [21].
Selective attachment was carried out to repurify the endo-
metrial cells [22]. The endometrial cells were cultured in
phenol-red-free DMEM/Ham’s F12 (Invitrogen, Carlsbad,
CA) supplemented with 10 % v/v fetal bovine serum (FBS;
Invitrogen), 100 μg/ml streptomycin, 100 U/ml penicillin
and 2 μg/ml of Fungizone to confluence. Next, they were
subjected to differential trypsinization and attachment for
further purification. They were then washed in phosphate-
buffered saline (PBS; pH = 7.4) and selectively trypsinized
with a 1:6 dilution of 1× trypsin/EDTA (Sigma) until the
contaminating stromal cells were removed. After washing
the cells in PBS, the trypsin/EDTA solution was removed,
and epithelial cells were plated (2 × 104 cells/ml) in dishes
in DMEM/Ham’s F12 supplemented with 10 % charcoal-
dextran stripped FBS (Invitrogen).
Immunocytochemistry
The procedure used for immunocytochemical staining
has been described previously [23]. Briefly, EECs were
cultured on a sterile cover glass in six-well plates.
When 70 % confluence was reached, cells were fixed
with 4 % paraformaldehyde at room temperature for
30 min. Vimentin (Vim), pan CK, OPN and MMP-9
(Abcam for all) were used as the primary antibodies.
The dilution ratios were as follows: vimentin (1:500),
pan CK (1:500), OPN (1:200) and MMP-9 (1:300).
Next, cells were incubated with a secondary antibody
(PV9000; Zymed Laboratory, South San Francisco)
and visualized with 3, 3’-diaminobenzidine tetrahydro-
chloride (DAB; Golden Bridge, Beijing, China). Cells
were then subjected to nuclear counterstaining (blue
staining) with hematoxylin.
Drug intervention
When EECs reached 60 % confluence, the media was dis-
carded and the cells were cultured in DMEM/Ham’s F12
without FBS for 12 h. Next, the media were changed to
DMEM/Ham’s F12 plus 10 % charcoal-dextran stripped
FBS supplemented with E2 at 0, 0.1, 0.5, 1, 5 or 10 nM,
and EECs were cultured for 48 h. The mRNA levels of
OPN and MMP-9 reached their maximum at a specific E2
concentration called the optimum concentration. EECs
were again cultured according to the protocols described
above. We treated EECs with the optimum concentration
of E2 for 0, 12, 24, 36, 48, 60 or 72 h. At each time point,
the mRNA levels of OPN and MMP-9 were determined
by real-time RT-PCR. The time point at which the
mRNAs of OPN and MMP-9 peaked was referred to as
the optimum time point. In the subsequent experi-
ments, including flow cytometry, gene silencing, west-
ern blots and gelatin zymography, EECs were treated
with E2 at the optimum concentration and time point.
Each experiment was performed three times, and each
group was repeated in triplicate.
Flow cytometry
After EECs were treated with E2 for 48 h (the optimum
time point) to allow for adequate protein synthesis, fluo-
rescently tagged mouse-anti-human MMP-9 antibodies
(BD Biosciences) wasused to detect antigens on the cells
according to the following procedure. Approximately 1 ×
106 cells were fixed with PBS containing 4 % paraformal-
dehyde for 30 min. After the EECs were washed in PBS
three times, they were suspended in PBS supplemented
with 0.5 % bovine serum albumin (BSA). EECs were
blocked with 1 mg of mouse IgG (Beyotime Biotechnol-
ogy, Jiangsu, China) for 15 min and then incubated with
Table 1 Clinical characteristics of patients
Control Endometriosis
Age (mean ± SD) 30.5 ± 1.1 32.4 ± 4.2
Age range (yr) 27-35 21-38
rAFS staging: I–II/III–IV 10/22
Menstrual cycle: P/S 18/12 19/13
P, proliferative phase; S, secretory phase
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the OPN and MMP-9 antibodies at room temperature for
1 h. Unbound antibodies were removed by washing with
PBS, and cells were again resuspended in PBS. EECs were
analyzed on a FACSAria II Flow Cytometer (BD Biosci-
ences, San Jose, USA). EECs not stained with antibodies
were used to define gating. EECs not treated with E2 were
used as controls.
Gene silencing
EECs were divided into two groups (siRNA-OPN and
siRNA-scrambled). Scrambled siRNA was used as a
negative control. The OPN siRNA sequences were as
follows: sense, 5′ -GGUCAAAAUCUAAGAAGUUTT-3′
and antisense, 5′-AACUUCUUAGAUUUUGACCTC-3′;
the scrambled siRNA sequences were as follows: sense,
5′-UUCUCCGAACGUGUCACGUTT-3′ and antisense,
5′-ACGUGACACGUUCGGAGAATT-3′. All of the siR-
NAs were designed and purchased from Shanghai Gene-
Pharma Inc. The siRNA oligonucleotides were transfected
into EECs using X-tremeGENE reagent (Roche Diagnos-
tics). The ratio of transfection reagent to siRNA was 10 μl:
2.5 μg per 2 × 105 cells. The transfection procedure was
carried out according to the manufacturer's instructions.
The efficiency of siRNA interference was examined by
western blot 72 h later.
RNA extraction and real-time RT-PCR
Trizol (Invitrogen), chloroform, isopropanol and ethanol
were successively used to extract the total RNA from the
EECs. RNA concentration was assessed using a Nano-
Drop spectrophotometer (Thermo Scientific, Waltham,
MA). For each sample, 1 μg of total RNA was used to
synthesize cDNA with a TIANscript reverse transcrip-
tion kit (TIANGEN Biotech, Beijing, China) according
to the manufacturer’s instructions. Real-time RT-PCR
was performed in triplicate for each sample using SYBR
Premix Ex Taq II (TaKaRa Biotech, Dalian, China) ac-
cording to the manufacturer’s instructions. Reactions
were carried out using a Roche LightCycler480. Amplifica-
tion of beta-actin was used for normalization. The primers
used in this assay were as follows: OPN: sense 5’- ACAG
CCGTGGGAAGGACAGTTA -3’, antisense, 5’- CCTGAC
TATCAATCACATCGGAATG -3’; MMP-9: sense, 5’-AG
TCCACCCTTGTGCTCTTCCC -3’, antisense, 5’-TCTGC
CACCCGAGTGTAACCAT-3’; beta-actin: sense, 5’-AGC
GAGCATCCCCCAAAGTT-3’, antisense, 5’-GGGCACG
AAGGCTCATCATT-3’. The relative expression levels of
each gene were determined with the 2−ΔΔCt method [24].
Western blot
A total of 1 × 107 EECs was washed twice with cold PBS
and then harvested in 250 μl RIPA lysis buffer with 10 μl
protease inhibitor cocktail (Sigma-Aldrich). Protein ali-
quots (50 μg) were run on a 10 % SDS polyacrylamide gel
and transferred to a nitrocellulose membrane (Amer-
sham). The membrane was blocked in 5 % milk in PBS
containing 0.1 % Tween 20 (PBS-T) at room temperature
for 1 h. The membrane was incubated with 1 % milk in
PBS-T containing a mouse anti-human monoclonal OPN
(1:1,000, Abcam) or MMP-9 (1:500, Abcam) antibody at
4 °C overnight. A rabbit anti-human polyclonal beta-actin
antibody (1:2,000; Beyotime) was used as the internal
control. The membrane was then probed with goat anti-
mouse or anti-rabbit IgG conjugated to horseradish per-
oxidase (1:5,000 for both; Beyotime) in 1 % milk in PBS-T
for 1 h. Immunoreactive proteins were detected with an
enhanced chemiluminescence (ECL) reagent (Amersham)
and exposed to X-ray film (FUJIFILM, Japan). The optical
density of each band was analyzed with ImageJ (http://
rsb.info.nih.gov/ij/download.html).
Gelatin zymography
EECs were treated with siRNA or E2 according to the pro-
cedures described above. For the siRNA-OPN+ E2 group,
EECs were treated with siRNA-OPN and E2 together with
the same concentrations used in the separate drug treat-
ment described above for 48 h. The enzymatic activity of
MMP-9 in the media was detected with gelatin zymogra-
phy as described previously with minor modifications
[25]. Briefly, the conditioned media were subjected to
10 % polyacrylamide gel electrophoresis in gels containing
1 mg/ml gelatin. Next, the gels were washed with 2.5 %
Triton X-100 (v:v) and 50 mM Tris–HCl (pH 7.5) at room
temperature for 2 h. After that, the gels were incubated in
a buffer supplemented with 10 mM CaCl2, 150 mM NaCl
and 50 mM Tris–HCl (pH 7.5). The gels were then
stained with 0.25 % (w/v) Coomassie blue R-250 in 30 %
methanol and 10 % acetic acid for 30 min at room
temperature and then de-stained with a solution contain-
ing 50 % methanol and 10 % acetic acid to show areas
with gelatinase activity. The gels were photographed with
Bio-Rad Gel Doc XR+, and the gray density of the bands
was analyzed using Image Lab™ Software, Version 3.0.
Transwell assay
One layer of 2 % Matrigel was used to cover the top
chamber of 24-well micropore polycarbonate mem-
brane inserts (8 μm; Millipore, Billerica, MA). EECs
were treated with siRNA-OPN, E2 or siRNA-OPN + E2
as described above. Approximately 1 × 105 trypsinized
cells per well were seeded into the top chamber using
FBS-free DMEM/Ham’s F12. DMEM/Ham’s F12 with
10 % charcoal-dextran stripped FBS was added to the
lower chamber as a chemoattractant. The plate was
placed at 37 °C for 24 h. Assays were then stopped by
removing the non-invading cells in the top chamber
with swabs. Cells on the lower surface of the membrane
were fixed with 4 % paraformaldehyde and stained with
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hematoxylin. Cells in five visual fields per insert were
counted and photographed (400× magnification).
Wound scratch assay
EECs were evenly plated in a 12-well culture plate (1 × 106
cells/well) and allowed to reach 90 % confluence. Wounds
were made by scratching the cell layer using a 1000-μl
sterile pipette tip along a ruler. Cellular debris was re-
moved thoroughly by washing the scratched area repeat-
edly with PBS. In the presence of serum, untreated cells
should migrate and fill the scratch area after approxi-
mately 72 h. Forty-eight hours after scratching, different
treatments displayed remarkable effects on cellular migra-
tion in preliminary experiments, so this time point was
chosen to end the assay. EECs were treated with siRNA-
OPN, E2 or siRNA-OPN+ E2 as described above. Images
were acquired using an Olympus IX71 inverted micro-
scope (100× magnification). The images shown are repre-
sentative of three independent experiments. The area
of unfilled wounds in five random fields was mea-
sured with ImageJ for further quantitative analysis.
Wound area (%) = 48-h scratch wound/0-h scratch
wound × 100 %.
Statistics
All repeated data are shown as the mean ± SEM. A one-
way ANOVA was used to compare the differences
among NEECs and EEECs for various treatments. P
values < 0.05 were considered statistically significant.
SPSS 15.0 (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses. PRISM 5.0 for Windows (GraphPad,
San Diego, CA, USA) was used to create the histograms.
Results
Identification of the primary cultured cells
Using primary culture techniques, we successfully isolated
EECs. EECs grew clonally in clumps and displayed a typ-
ical cobblestone morphology (Fig. 1a). To ensure that the
cultured cells were endometrial epithelial cells, we identi-
fied different cell markers with immunocytochemistry. As
expected, most cells were positive for pan CK (immuno-
staining in the cytoplasm) but negative for vimentin
(Fig. 1a). The pan CK biomarker is characteristic of cells
of epithelial origin, whereas vimentin labels cells to be of
mesenchymal origin. The successful primary culture of
endometrial epithelial cells laid the foundation for subse-
quent assays.
Detection of OPN and MMP-9 expression in EECs by
immunocytochemistry
We detected the expression levels of OPN and MMP-9 in
the primary cultured EECs by immunocytochemistry.
OPN immunostaining was located in the cytoplasm of
most EECs, and the MMP-9 distribution pattern was simi-
lar to that of OPN (Fig. 1a).
Quantification of the OPN and MMP-9 expression levels
with real-time RT-PCR and western blots
To compare the quantitative differences in OPN and
MMP-9 expression levels in NEECs and eutopic EECs
with endometriosis (EEECs), we performed real-time RT-
PCR and western blots. We used the 2−ΔΔCt method to
obtain the relative expression values of these two genes.
To normalize the expression levels of OPN and MMP-9,
the relative gene expression levels from NEECs were set
to 1, and the normalized mRNA expression of OPN from
stage I/II and stage III/IV EEECs were 1.59 and 3.32, while
those of MMP-9 were 1.68 and 3.14, respectively (Fig. 1b).
Statistical analysis showed that significant differences in
the expression levels of OPN and MMP-9 existed between
any two groups of NEECs, stage I/II and stage III/IV
EEECs (p = 0.031). Similarly, the gray density ratio of OPN
(MMP-9)/beta-actin was used to represent the relative ex-
pression levels of these two proteins. After normalization,
the expressions of OPN from stage I/II and stage III/IV
EEECs were 1.69 and 3.01, while those of MMP-9 were
1.57 and 2.79, respectively (Fig. 1c). There were significant
differences in the expression levels of OPN and MMP-9
between any two groups of NEECs, stage I/II and stage
III/IV EEECs (p = 0.028). The relative gene expression
levels of OPN and MMP-9 in the proliferative phase from
NEECs were set to 1. The normalized mRNA expressions
of OPN and MMP-9 in the secretory phase of NEECs
were 1.45 and 1.56. Similarly, the OPN mRNA expression
in the proliferative phase and secretory phase of EEECs
were 2.61 and 3.60, while that of MMP-9 was 2.74 and
3.31, respectively. Significant differences in the expression
levels of OPN and MMP-9 were observed when compar-
ing different stages of the menstrual cycle in both NEECs
and EEECs (p = 0.025) and also in the same stage of the
menstrual cycle when comparing NEECs and EEECs (p =
0.0031). We also compared the normalized protein ex-
pressions of OPN and MMP-9 in different menstrual cycle
stages in NEECs and EEECs, and significant differences
were found between different menstrual cycle stages in
both NEECs and EEECs (p = 0.010) and between NEECs
and EEECs in the same menstrual cycle stage (p = 0.0015).
The expression levels of OPN and MMP-9 from NEECs
were lower overall than those from EEECs.
E2 induced OPN and MMP-9 expression
To determine whether the OPN and MMP-9 expression
levels were influenced by E2, we treated EECs with E2.
Using real-time RT-PCR, we found an escalating trend
in OPN and MMP-9 expression with increasing doses of
E2; the normalized expression levels peaked at 10 nM
E2. This trend was observed in both NEECs and EEECs
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(Fig. 2a). We also conducted a time-course experiment
with E2 and found that the OPN and MMP-9 expression
levels in NEECs and EEECs increased over time (Fig. 2b).
OPN and MMP-9 expression levels reached their
maximum 48 h after the beginning of the intervention.
Forty-eight hours and 10 nM were the optimum time and
concentration for E2 treatment. However, the trends for
the dose-dependent and time-dependent reactions from
NEECs were weaker than those observed from the EEECs.
For NEECs and stage I/II and stage III/IV EEECs, E2 treat-
ment remarkably up-regulated OPN and MMP-9 expres-
sion (p = 0.018). Significant differences existed between any
two groups of NEECs and stage I/II and stage III/IV EEECs
after E2 treatment at 10 nM for 48 h (Fig. 2c, p = 0.032).
For both NEECs and EEECs and in both the proliferative
phase and secretory phase, the expression levels of OPN
and MMP-9 were significantly different between E2 treat-
ment and the untreated condition (Fig. 2d, p = 0.023). Flow
cytometry confirmed that the expression of MMP-9 on the
surfaces of EEECs was remarkably elevated after 48 h of E2
treatment compared with the NEECs (Fig. 2e). For EEECs,
the expression of OPN and MMP-9 in stage III/IV was
much higher than that in stage I/II.
MMP-9 expression reduced upon OPN inhibition by siRNA
knockdown
To determine whether MMP-9 expression is regulated by
OPN in a signaling pathway similar to that observed in
cancer cells, we used siRNA interference to downregulate
OPN. OPN expression was specifically downregulated by
Fig. 1 Vim, pan CK, OPN and MMP-9 were identified in EECs with immunocytochemistry. a The isolated EECs display distinct cobblestone morphology
and express pan CK instead of Vim. OPN and MMP-9 are located in the cytoplasm of EECs. OPN and MMP-9 expression levels are detected in NEECs
and EEECs with real-time RT-PCR (b) and western blots (c). *, I/II EEECs vs. NEECs, p < 0.05; **, III/IV EEECs vs. NEECs, p < 0.01. Real-time RT-PCR (d) and
western blots (e) show that OPN and MMP-9 expression is detected in NEECs and EEECs. *, proliferative phase EEECs vs. proliferative phase
NEECs, p < 0.05; **, secretory phase III/IV EEECs vs. secretory phase NEECs, p < 0.01. p, proliferative phase; s, secretory phase. The histogram
represents three independent assays. Data are presented as the mean ± S.E. The housekeeping gene beta actin was used to normalize the
expression levels of OPN and MMP-9
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siRNA-OPN in NEECs and EEECs (Fig. 3a). There was a
significant difference in OPN expression levels between
the siRNA-OPN and siRNA-scrambled groups in NEECs,
stage I/II EEECs and stage III/IV EEECs (p = 0.042). Along
with OPN, MMP-9 expression was markedly decreased in
both stage I/II and stage III/IV EEECs, which was signifi-
cantly different from the siRNA-scrambled condition (p =
0.033). However, after siRNA treatment, MMP-9 expres-
sion barely changed in NEECs (p = 0.21). To observe the
enzymatic activity of MMP-9, we performed gelatin zymo-
graphy. The conditioned media were collected from
NEECs and EEECs. For both cell types, EECs were cul-
tured with siRNA-scrambled, siRNA-OPN, E2, siRNA +
E2 or without intervention (untreated). The gray density
Fig. 2 E2 induced OPN and MMP-9 expression in EECs. A dose–dependent response (a) and a time-dependent response (b) based on real-time
RT-PCR depicts the changes in OPN and MMP-9 expression after stage III/IV EEECs were treated with E2. Typical bands of western blots and the
histogram are shown for E2 treatment at the optimum concentration (10 nM) and time point (48 h) grouped by rAFS staging (c) or by menstrual
cycle (d). (e) The detection of MMP-9 cell-surface expression levels by flow cytometry. p, proliferative phase; s, secretory phase. 1, 3, 5 and 7 are
the untreated condition; 2, 4, 6 and 8 are the E2 treatment. The histogram represents three independent assays. Data are presented as the
mean ± S.E. *, p < 0.05 for differences between cell types with the same treatment
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Fig. 3 (See legend on next page.)
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of gelatin zymography showed that for NEECs, the protein
levels of proMMP-9 and MMP-9 hardly changed in any of
the intervention conditions (p = 0.34). The proMMP-9
and MMP-9 levels from stage I/II and stage III/IV EEECs
decreased in the siRNA-OPN condition and increased in
the E2 treatment group compared with the untreated
group (p = 0.017). For the siRNA +OPN groups, the
proMMP-9 and MMP-9 levels fell between those of the
siRNA-OPN and E2-only groups. We observed that the
gray density of EEECs was stronger than that observed
in NEECs (Fig. 3b). We also calculated the MMP-9/
proMMP-9 ratio and found that the numeric values de-
rived from NEECs were lower than those from EEECs.
For the siRNA-OPN, siRNA-OPN + E2 and E2 treat-
ments, there were significant differences between any
two groups of NEECs and stage I/II and stage III/IV
EEECs (p = 0.025).
E2 and siRNA intervention changed the migratory ability
of EEECs
To observe the differences in the migration abilities of
EECs influenced by E2 and siRNA intervention, we per-
formed Transwell and wound scratch assays. For NEECs
and EEECs, the numbers of cells counted on the lower sur-
face of the insert membrane of the Transwell for each treat-
ment were E2, siRNA+ E2, untreated, siRNA-scrambled
and siRNA-OPN in descending order (Fig. 4). E2 was
clearly the strongest impetus promoting the migration of
EECs, and siRNA-OPN had the strongest ability to inhibit
the migration of EECs. Statistical analysis showed that there
were significant differences between any two groups of
NEECs and stage I/II and stage III/IV EEECs for each of
the E2, siRNA+ E2 and siRNA-OPN treatments (p =
0.040). Similarly, EECs had the strongest ability to migrate
after E2 treatment and left the smallest unfilled scratch
area. For the siRNA+ E2, untreated, siRNA-scrambled and
siRNA-OPN treatments, the migratory abilities decreased
in wound scratch assays (Fig. 5). Significant differences
were observed between any two groups of NEECs and stage
I/II and stage III/IV EEECs for the same treatment (p =
0.028).
Discussion
Endometriosis is a common but complex disorder that is
believed to be caused by the interaction of various bio-
active factors such as steroid hormones, immunological
molecules, genetic materials and environmental toxins
[1, 26]. According to the theory of retrograde menstru-
ation, endometrial cells can disaffiliate from the normal
position and attach to and invade tissues outside the
uterus in a manner similar to cancer cell metastasis.
That is, a series of actions including disaffiliation, attach-
ment and invasion are of great importance for the devel-
opment of early endometriosis, and EECs are thought to
play an important role in these processes [27]. Many
proteins have been reported to correlate with the patho-
logical process of cancers, as well as the pathogenesis of
endometriosis [28, 29]. OPN, a protein implicated in the
adhesion and migration of cancer cells, was evaluated in
normal endometrium and endometrium from individuals
with endometriosis. We performed primary EEC culture
to exclude the possibility of contamination of endometrial
stromal cells. We found that the expression of OPN in
EEECs was significantly higher than that in the NEECs.
We also found that MMP-9 expression increased in syn-
chrony with increased OPN expression in NEECs and
EEECs, which is in agreement with previous reports [11,
14]. For EEECs, the OPN and MMP-9 expression in stage
III/IV was higher than in stage I/II. For both NEECs and
EEECs, the expression of OPN and MMP-9 was much
higher in the secretory phase than in the proliferative
phase, which is consistent with previous studies [7, 9].
These results suggest that a cause-and-effect relationship
exists between the expression levels of OPN and MMP-9
and that elevated expression of OPN and MMP-9 may ini-
tiate the disaffiliation, adhesion and migration of the
endometrium to tissues outside the uterus.
To explore whether the elevated expression levels of
OPN and MMP-9 in the EEECs are regulated by estrogen,
we determined the expression levels of OPN and MMP-9
in NEECs and EEECs after cells were treated with E2.
During both the dose–response and the time-course stud-
ies, we found that E2 prompted elevated expression of
OPN and MMP-9, with a stronger increase observed in
EEECs. We also found that after the E2 treatment, the sur-
faces of EEECs exhibited greater expression of OPN and
MMP-9 than the corresponding NEECs. For EEECs, the
expression of OPN and MMP-9 on cellular surfaces was
much higher in stage III/IV than in stage I/II, which sug-
gested that the OPN and MMP-9 expression levels corre-
lated with the severity of endometriosis or the local E2
concentration. Estrogen is considered a key hormone in
the pathogenesis of endometriosis and it exerts its func-
tions by binding to its receptors (mainly ER-alpha and ER-
(See figure on previous page.)
Fig. 3 The MMP-9 expression levels and enzymatic activities were detected with western blots and gelatin zymography, respectively, after various
treatments. a Typical bands from western blots and the histogram are shown for OPN-specific siRNA treatments. 1, 3 and 5 are siRNA-scrambled; 2, 4
and 6 are siRNA-OPN. b Representative bands of gelatin zymography and the histogram show the enzymatic activities of MMP-9. The histogram
represents three independent assays. Data are presented as the mean ± S.E. *, p < 0.05 for differences between cell types with the same treatment
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beta). Estrogen receptors have been found to be overex-
pressed in endometriosis compared with levels in the
normal endometrium [30, 31]. Long-term local estro-
gen accumulation may be responsible for the overex-
pression of estrogen receptors. Excessive binding of
estrogen to receptors activates the expression of down-
stream genes, many of which play an important role in
cell migration. In short, our data support the hypothesis
that E2 is a key factor in promoting the overexpression
of OPN and MMP-9 in EEECs.
In cancer cells, the OPN/MMP-9 signaling pathway has
been reported [5, 6]. To investigate whether a similar
pathway exists in EEECs, we performed siRNA interfer-
ence to specifically down-regulate OPN. Not surprisingly,
in EEECs the decreased expression of OPN was accom-
panied by down-regulated expression of MMP-9. We also
treated EEECs with E2 and siRNA-OPN simultaneously.
The results show that E2 antagonizes the inhibitory effects
of siRNA-OPN on the expressions of OPN and MMP-9.
Hence, our data indicate that an MMP-9 signaling path-
way regulated by OPN under the local E2 environment ex-
ists in EEECs. Interestingly, MMP-9 expression changed
only minimally upon OPN down-regulation in NEECs.
One possible explanation for this phenomenon is that
MMP-9 is regulated by many different signaling path-
ways, and some signaling pathways are activated during
the biological and morphological transformation from
NEECs to EEECs. For example, TGF-beta1 and epider-
mal growth factor can induce EEECs to migrate by se-
lectively activating Raf-1; however, this regulatory pathway
has not been reported in NEECs [32]. Combined with the
data obtained from the E2 intervention, we infer that
OPN may regulate MMP-9 expression in a fluctuating
local estrogen environment.
To determine whether there are differences in the
amount of proMMP-9 compared with its active counter-
part in NEECs and EEECs under various interventions,
we performed gelatin zymography. The experimental
data showed distinct bands of both proMMP-9 and ac-
tive MMP-9 in all treatment conditions. The amount of
MMP-9 in NEECs was less than that in EEECs. Tissue
inhibitors of metalloproteinases (TIMPs), which affect
matrix remodeling in normal and pathological condi-
tions, regulate the activity of MMP-9 and maintain the
Fig. 4 Typical pictures of Transwell assays and the histogram show the altered migration ability of EECs after various interventions. The histogram
represents three independent assays. Data are presented as the mean ± S.E. Differences were compared between different cell types with the
same treatment, *, p < 0.05, **, p < 0.01
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homeostasis in endometrial migration [33]. In fact, the ra-
tios of MMPs and TIMPs have been correlated with the
development and progression of endometriosis [34].
TIMPs were reported to have lower expression in endo-
metriosis than in normal conditions. The lower expression
of TIMPs in endometriosis means that less MMP-9 is de-
graded, and EEECs are much more prone to migration.
ProMMP-9 is synthesized as a latent, inactive zymogen
that can be activated by a number of proteases. In normal
and pathological conditions, the expression profiles of
proteases are different. New proteases have been found to
proteolytically activate proMMP-9 in some cancers but
not in the original normal tissues [35]. Our data showed
that the ratio of MMP-9/proMMP-9 in NEECs was lower
than that in EEECs. These data are in accordance with
previous reports [36] and may also be explained by two
observations, namely, the reduced MMP-9 degradation
and enhanced proMMP-9 activation in EEECs. E2 and
OPN are located at specific regulatory sites in the sup-
posed E2/OPN/MMP-9 signaling pathway. Using gelatin
zymography, we reconfirmed that MMP-9 is regulated by
E2 and OPN via treatment with E2 and OPN-specific
siRNA treatment.
To confirm that the migration of EEECs could be af-
fected by the regulation of the E2/OPN/MMP-9 pathway,
we performed Transwell and wound scratch assays with
different treatments. We found that the number of cells
on the lower surface of the membrane and the scratch
area left unfilled varied in line with the quantitative
changes in OPN and MMP-9 expression caused by the
same treatment. These data showed that the E2/OPN/
MMP-9 pathway was active in EEECs. We also found that
E2 could significantly promote the migration of NEECs,
although this effect was inferior to that observed in
EEECs. Our data suggest that there may be another signal-
ing pathway that regulates cell migration in NEECs but
not in EEECs, which needs to be explored further.
In summary, we performed multiple assays to observe
the differential expression of OPN and MMP-9 under
various treatment conditions. The aim of these assays
Fig. 5 Representative images and the histogram show the results of the wound scratch assay after diverse treatments of NEECs and EEECs. The
histogram represents three independent assays. Data are presented as the mean ± S.E. Differences were compared between different cell types
with the same treatment, *, p < 0.05, **, p < 0.01
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was to establish a new signaling pathway in which up-
regulation of MMP-9 via activation of OPN induced by
estrogen correlates with the migration of endometrial
epithelial cells in endometriosis. The basic framework of
this signaling pathway has now been established; how-
ever, the detailed molecular interactions between E2 and
OPN or OPN and MMP-9 are not yet fully elucidated.
Additional research will help to elucidate these subjects
in the future.
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